Shire's ADHD drug Vyvanse gets US label update
This article was originally published in Scrip
Executive Summary
Shire has added new supplementary data to the US label of its ADHD treatment Vyvanse (lisdexamfetamine dimesilate) which shows efficacy data at 14 hours post-dose for adult patients.